Pounds of prevention: Obesity therapy

American Heart Journal

Volumn 142, Issue 3, 2001, Pages 388-390

  Patel, Manesh R ^a   McGuire, Darren K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CLOFIBRATE; DEXFENFLURAMINE; DOXAZOSIN; ENCAINIDE; ESTROGEN; FENFLURAMINE; LEPTIN; MIBEFRADIL; NIFEDIPINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TROGLITAZONE;

BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EDITORIAL; ENERGY CONSUMPTION; ENERGY EXPENDITURE; EPIDEMIC; HEALTH CARE COST; HUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; WEIGHT GAIN;

EID: 0034871014     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.117511     Document Type: Article

References (11)

1. Obesity
2. Overweight, obesity, and health risk
3. Body-mass index and mortality in a prospective cohort of US adults
4. Positional cloning of the mouse obese gene and its human homologue
5. Leptin
6. The role of leptin in human, obesity and disease: A review of current evidence
7. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997
8. Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat: A randomized controlled trial
9. Effect of sibutramine on weight maintenance after weight loss: A randomized trial
10. Obesity in heart disease